Company Filing History:
Years Active: 2011
Title: Gertraud Orend: Innovator in Cancer Research
Introduction
Gertraud Orend is a notable inventor based in Pratteln, Switzerland. She has made significant contributions to the field of biomedical research, particularly in cancer diagnosis and treatment. Her innovative work has led to the development of a patent that addresses critical challenges in oncology.
Latest Patents
Gertraud Orend holds a patent titled "Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer." This patent describes the FNIII13 domain of fibronectin and its smaller fragments, which exhibit a tumor cell proliferation inhibitory effect. The compositions provided in her patent comprise fragments of fibronectin that have the FNIII 13 domain. Additionally, the patent outlines a system that utilizes cells exposed to fibronectin, which are caused to proliferate by the presence of tenascin, as an in vitro method for screening potential anti-tumor agents. Furthermore, cell-free systems that include a fibronectin ligand and tenascin are employed for screening possible anti-tumor or anti-cancer agents. Test compounds are assessed for their ability to disrupt the binding of the fibronectin ligand to tenascin. A further cell-free system also incorporates a syndecan molecule.
Career Highlights
Gertraud Orend is associated with the Novartis Forschungesstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research. Her work at this prestigious institution has allowed her to focus on groundbreaking research in cancer treatment and diagnostics.
Collaborations
One of her notable collaborators is Ruth Chiquet-Ehrismann, who has contributed to the research efforts in the field.
Conclusion
Gertraud Orend's innovative work in cancer research exemplifies the impact of scientific inquiry on medical advancements. Her patent and collaborations highlight her commitment to improving cancer diagnosis and treatment.